Advicenne S.A. (ALDVI.PA)
- Previous Close
1.8700 - Open
1.8860 - Bid --
- Ask --
- Day's Range
1.8500 - 2.0500 - 52 Week Range
1.1000 - 4.3203 - Volume
79,803 - Avg. Volume
62,696 - Market Cap (intraday)
23.976M - Beta (5Y Monthly) 1.26
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6700 - Earnings Date Mar 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.30
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
www.advicenne.comRecent News: ALDVI.PA
Performance Overview: ALDVI.PA
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALDVI.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALDVI.PA
Valuation Measures
Market Cap
22.48M
Enterprise Value
34.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.09
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-215.28%
Return on Assets (ttm)
-31.25%
Return on Equity (ttm)
--
Revenue (ttm)
3.27M
Net Income Avi to Common (ttm)
-7.03M
Diluted EPS (ttm)
-0.6700
Balance Sheet and Cash Flow
Total Cash (mrq)
5.25M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.95M
Research Analysis: ALDVI.PA
Company Insights: ALDVI.PA
ALDVI.PA does not have Company Insights